The future of clinical trials in secondary prevention after acute coronary syndromes
Key result
An ESC meeting proposed strategies to improve clinical trials in secondary prevention after acute coronary syndromes, including novel trial designs, refined endpoints, and increased use of registries.
Population
Patients with acute coronary syndromes (ACS) in the context of secondary prevention clinical trials
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May guide future post-ACS trial methodology; leaves open whether novel designs and registries will improve efficiency or validity.
Structured PICO
P
Population
Patients with acute coronary syndromes (ACS) in the context of secondary prevention clinical trials
This ESC consensus document outlines methodological strategies to address the growing complexity and cost of clinical trials in secondary prevention after acute coronary syndromes.
Limitations
- Patients treated in routine clinical practice differ largely from trial participants, limiting external validity.
- Interpretation of composite endpoints is often complex.
- Surrogate endpoints are often unreliable predictors of clinical outcomes.
Cite This Study
Bueno et al. (2010) conducted a review in Acute coronary syndromes. An ESC meeting proposed strategies to improve clinical trials in secondary prevention after acute coronary syndromes, including novel trial designs, refined endpoints, and increased use of registries.